Pharmafile - Business Services News
Posts 13% drop in net income as generic version of Gleevec launched
Sees minor increase in net sales compared to last year on the back of low growth in global pharmaceutical markets
Says pharmaceuticals business continues to deliver impressive levels of growth
Expects wholesale channel inventory to drop to $7 million
The drug candidate is targeted to treat non-small cell lung cancer in patients who have already had therapy for the disease
AML is an aggressive blood cancer and treatment options have stagnated in over three decades
Trial showed overall survival rose by 19% and the drug also improved quality of life
Hopes to close deal by mid-2016 and says merger is targeted at creating a global biotechnology firm focused on rare diseases
J&J to also invest $50 million in Tesaro’s stock
Pfizer to pay $150 million in reimbursement to Allergan